StockNews.com upgraded shares of Ionis Pharmaceuticals (NASDAQ:IONS – Free Report) from a sell rating to a hold rating in a research report sent to investors on Wednesday. IONS has been the topic of several other research reports. Needham & Company LLC reiterated a buy rating and issued a $60.00 price target on shares of Ionis […]
Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Get Free Report) have received a consensus rating of “Moderate Buy” from the fourteen brokerages that are presently covering the firm, MarketBeat reports. Two investment analysts have rated the stock with a sell recommendation, four have assigned a hold recommendation, seven have issued a buy recommendation and one […]
Ionis Pharmaceuticals (NASDAQ:IONS – Get Free Report) was upgraded by research analysts at StockNews.com from a “sell” rating to a “hold” rating in a note issued to investors on Wednesday. A number of other brokerages also recently issued reports on IONS. Stifel Nicolaus increased their price objective on Ionis Pharmaceuticals from $45.00 to $50.00 and […]
BLB&B Advisors LLC decreased its holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Free Report) by 1.8% in the third quarter, Holdings Channel reports. The firm owned 147,650 shares of the company’s stock after selling 2,650 shares during the quarter. BLB&B Advisors LLC’s holdings in Ionis Pharmaceuticals were worth $6,697,000 as of its most recent SEC […]
Simplicity Solutions LLC lowered its stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Free Report) by 2.1% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 12,198 shares of the company’s stock after selling 267 shares during the period. Simplicity Solutions LLC’s holdings in Ionis […]